LIANY · LianBio · Metrics
Market Cap
$4.21M
Shares
108.06M
Volume · Nov 2
9100
Avg daily vol (3M)
17.05K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
LIANY metrics
57 of 125 screener metrics currently available.
Market overview
2 metricsShare price
$0.04
Market cap
$4.21M
Price action
23 metricsPrice change (1W)
-35.3%
Price change (30D)
-23.9%
Price change (3M)
-19.2%
Price change (6M)
-68.2%
Price change (YTD)
-59.2%
Price change (1Y)
-44.6%
Trailing year
Price change (5Y)
-99.7%
52-week high
$0.18
52-week low
$0.03
Change from 52-week high
-78.1%
Change from 52-week low
+21.3%
Annualized volatility
245.6%
Annualized volatility (3M)
—
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
-1.4
RSI (14D)
40.2
Price vs SMA 50
-27.5%
Price vs SMA 200
-53.2%
Avg volume (3M)
17,049
Relative volume
0.5
Average dollar volume
$727
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
108.06M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.0
reciprocal yield 4,801.1%
FCF yield
-1,992.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-2,087.6%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
0
Last ex-dividend
2025-07-15
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$106.56M
Net income (TTM)
−$87.98M
Trailing 12 months
Diluted EPS (TTM)
$-0.81
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-1.1%
Year over year · fewer shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-43.5%
Return on assets
-33.5%
Debt / equity
—
Current ratio
10.1
EBITDA (TTM)
—
Free cash flow (TTM)
−$83.99M
Quick ratio
10.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$252.22M
Latest balance sheet
Cash & equivalents
$103.46M
Total assets
$262.90M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$83.53M
Capital expenditures (TTM)
$464,000
R&D (TTM)
$39.88M
SG&A (TTM)
—
Stock compensation (TTM)
$18.52M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—
Ownership (registered funds)
1 metricsIndex-fund ownership
0.0%
Short interest
3 metricsShort interest
0.0%
Latest settlement · 3.9 days to cover
Days to cover
3.9d
Short-squeeze score
28 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—